Valeant Pharmaceuticals International Inc (NYSE:VRX)(TSX:VRX) stated on Thursday that it plans to pay down another USD200m of its senior secured term loans with cash on hand.
Following the repayment of debt next week, the company will have reduced its debt, in aggregate, by more than USD6.7bn since the end of Q1 2016.
In conjunction, the company's total long-term debt will be about USD25.5bn.
The specialist pharmaceutical company develops, manufactures and markets a broad range of pharmaceutical products in dermatology, gastrointestinal disorders, eye health, neurology and branded generics.
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets